Increased competition among biotech VCs in China.
Shift from waiting for assets to proactively investing.
Focus on upstream scientific pipelines.
Strategic angle: U.S. venture capital firms are proactively investing in Chinese biotech, shifting their strategy as competition intensifies.
Increased competition among biotech VCs in China.
Shift from waiting for assets to proactively investing.
Focus on upstream scientific pipelines.